Latest posts
-
Does Evolocumab Cause Weight Gain?
A Patient-Reported Signal That Deserves Attention Journal of Diabesity | Advancing Metabolic Health The management of dyslipidemia has entered a transformative era with the introduction of PCSK9 inhibitors such as evolocumab. These agents have demonstrated profound LDL-cholesterol (LDL-C) lowering and cardiovascular risk reduction. However, emerging patient-reported data suggest a potential metabolic effect not previously emphasized
-
Tirzepatide for Heart Failure: New Study Confirms Major Benefits in HFpEF and Obesity
A groundbreaking clinical trial known as the SUMMIT study has revealed that tirzepatide, a dual-action medication already known for its success in managing type 2 diabetes and obesity, provides significant clinical benefits for patients with heart failure with preserved ejection fraction (HFpEF) — especially when it occurs alongside obesity. This new evidence is a game-changer